title: [Anti(lymph)angiogenic preconditioning prior to keratoplasty].
abstract: OBJECTIVE
  The aim of this study is to describe novel therapeutic concepts to promote graft survival in high-risk keratoplasty by targeting (lymph)angiogenesis in the transplant context.
  
  
  METHODS
  A PubMed literature search and our own clinical and experimental data are evaluated.
  
  
  RESULTS
  There are three options for anti(lymph)angiogenic preconditioning: a) primary prevention of neovascularisation during the disease process, b) secondary prevention by regressing established blood vessels prior to transplantation and (c) tertiary prevention through inhibition of post-keratoplasty neovascularisation.
  
  
  CONCLUSIONS
  Modern topical anti(lymph)angiogenic therapies seem to be able to reduce the risk of graft rejection especially in high-risk keratoplasty.
authors.affiliation: Universitätsaugenklinik, Universität zu Köln, Kerpener Strasse 62, Köln. claus.cursiefen@uk-koeln.de
authors.forename: C
authors.initials: C
authors.lastname: Cursiefen
authors.forename: B
authors.initials: B
authors.lastname: Regenfuss
authors.forename: D
authors.initials: D
authors.lastname: Hos
authors.forename: F
authors.initials: F
authors.lastname: Bucher
authors.forename: P
authors.initials: P
authors.lastname: Steven
authors.forename: L M
authors.initials: LM
authors.lastname: Heindl
authors.forename: F
authors.initials: F
authors.lastname: Bock
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D016510:Corneal Neovascularization / Q000209:etiology* / Q000517:prevention & control*; D016039:Corneal Transplantation / Q000009:adverse effects*; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D042583:Lymphangiogenesis / Q000187:drug effects*; D011292:Premedication / Q000379:methods; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors